Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Clario acquires WCG's neuroscience-focused clinical outcome assessment business
(1d)
Insilico Medicine raises $110M for new trials and robotic helping hands
(1d)
J&J’s Monarch bronchoscopy robot cleared by FDA to connect to live CT scans
(1d)
Manufacturer fuels Swiss biotech’s next-gen vaccine portfolio in new investment deal
(1d)
GSK posts data on HIV assets vying for roles in 6-month combo
(1d)
Harbour BioMed launches new obesity biotech on mission to preserve muscle mass
(1d)
Ono pays $280M upfront for Ionis' antisense oligonucleotide for rare blood cancer
(1d)
Roche pads out obesity pipeline, paying Zealand $1.6B upfront to co-develop amylin asset
(1d)
Roche pads out obesity pipeline, paying Zealand $1.6B upfront to codevelop amylin asset
(1d)
Boehringer Ingelheim teams with Veeva to launch new R&D platform One Medicine
(2d)
BioPharma Dive
MeiraGTx spins Parkinson’s, obesity gene therapies into AI startup
(5h)
Mallinckrodt, Endo to combine in $7B deal
(6h)
Roche broadens obesity drug plans with $1.65B Zealand deal
(1d)
A new obesity biotech launches; Gilead plans to quickly advance once-yearly PrEP for HIV
(1d)
Flagship startup raises $200M in pursuit of ‘scientific superintelligence’
(1d)
Ono pays $280M to license Ionis rare disease drug
(1d)
IRA reforms could be on the table. Will Trump and the GOP pursue them?
(1d)
Viking inks CordenPharma deal to boost obesity drug supply
(2d)
Merck opens $1B vaccine plant in North Carolina
(2d)
Arvinas gets positive breast cancer data, but finds differentiation a hard sell
(2d)
Endpoints News*
MeiraGTx partners with cryptic AI startup Hologen to advance Parkinson's gene therapy
(6h)
With Hinge Health filing to go public, are we... back?
(6h)
Acelyrin, Pliant turn to ‘poison pill’ as Kevin Tang’s Concentra pursues both companies
(7h)
Canada pitches in to Entos' facility build; Vetter expands in Germany
(7h)
White House pulls Weldon's nomination to lead CDC
(8h)
Updated: White House pulls Weldon's nomination to lead CDC
(8h)
Inside Pepper, a New York health tech professional community
(9h)
Endpoints wins SABEW award for Health Tech coverage
(9h)
GoodRx CEO Wendy Barnes on the future of the drug discount company
(10h)
Montara Therapeutics adds $20M to seed fundraise for neurology pipeline
(10h)
BioSpace
Trump Administration Pulls CDC Nominee Dave Weldon at Last Minute
(7h)
Houston’s Life Sciences Scene Continues Boosting Its Reputation
(7h)
Acelyrin Adopts Poison Pill to Ward Off Tang Capital Buy
(8h)
“Perfect Patient” Industry Burdens; Exits and Investment in Women’s Health
(8h)
Amgen's Uplizna Deepens Response Against Myasthenia Gravis at 1 Year
(8h)
J&J, Legend Pump $150M Into Manufacturing in Bid to Double Carvykti Production
(8h)
Troubled drugmakers Mallinckrodt, Endo Officially Announce $6.7B Merger
(9h)
Troubled Drugmakers Mallinckrodt, Endo Officially Announce $6.7B Merger
(9h)
Gilead, GSK-ViiV Move Ahead With Long-Acting HIV Options Following Early-Stage Readouts
(1d)
Good Day for Gardasil as Merck Wins Safety Suit, Drops $1B for Manufacturing Push
(1d)
Stat News*
The sudden withdrawal of a CDC nominee and what went wrong with Covid policies
(1h)
Study reveals how often medical device makers report safety incidents late to FDA
(6h)
Trump’s picks to run FDA and NIH win approval from Senate’s health committee
(7h)
A study on brains and a statement on driving
(8h)
Pharmalittle: We’re reading about senators probing telehealth, Boston’s slumping biotech hub and more
(8h)
White House pulls nomination of Dave Weldon as CDC director hours before hearing
(8h)
In the Boston area, biotech’s hub, a slump is being acutely felt
(9h)
Soleno Therapeutics’ ‘life-changing’ drug nears approval decision
(11h)
Top addiction researcher Nora Volkow on NIH cuts, optimism and the limits of RFK Jr.’s 12-step experience
(13h)
Biotech raising $35 million to take a second stab at cancer drug from Bert Vogelstein’s lab
(13h)
BioPharma Trend
Elsevier Launches ScienceDirect AI to Provide Summarized Research Insights
(6h)
Elsevier Launches AI to Provide Summarized Research Insights
(9h)
Tempus Acquires AI-Powered Clinical Trial Matching Platform
(10h)
Insilico Medicine Raises $110M to Advance AI Drug Design, Unveils its Humanoid Lab Robot
(1d)
Lila Sciences Raises $200M to Automate Scientific Discovery with AI and Robotics
(2d)
U.S. Judge Blocks NIH Grant Funding Cuts Amid Ongoing Litigation
(1w)
AI-Powered Immune Mapping Company Appoints Ex-Pfizer R&D Chief to Its Board
(1w)
Cortical Labs Launches $35K Biological Computer Built on Human Brain Cells
(1w)
Cortical Labs Introduces Biological Computer Built on Human Brain Cells
(1w)
Novo Nordisk and Gensaic Collaborate on Tissue-Targeted Therapies for Cardiometabolic Diseases
(1w)
Labiotech.EU
Nine biotechs thriving in Seattle in 2025
(8h)
Checkpoint inhibitors in cancer: breakthroughs, setbacks, and what’s next
(1d)
The gender gap in clinical trials: Why women are still underrepresented
(2d)
23andMe: the collapse of a genomics giant
(3d)
Catalonia: A biotech hub going from strength to strength, with Barcelona at its core
(6d)
[Rebroadcast] How AI immune system mapping can boost drug discovery
(6d)
Top biotech deals of February 2025
(1w)
Seven biotech companies keeping Taiwan dynamic in 2025
(1w)
The biggest biotech funding rounds in February 2025
(1w)
Rare Disease Day: seven drugs awaiting approval in 2025
(2w)
GEN News
Mallinckrodt, Endo Plan $6.7B Merger
(3h)
Structure of Key Parkinson’s Disease Protein, PINK1, Seen for First Time
(4h)
Batavia Biosciences Partners with VBC and MEVAC to Advance Localized Vaccine Manufacturing in Egypt
(4h)
DNA Nanostructures That Form Without Extreme Heat Could Boost Drug Delivery, Diagnostics
(19h)
Extrachromosomal DNA Carrying MYC Drives Pancreatic Cancer Aggression
(21h)
With $110M Financing Complete, Insilico Eyes Platform, Pipeline Progress
(1d)
Celonic Integrates Merck’s Breez Micro-Bioreactor Platform Into Its Process Development Operations
(1d)
Roche, Zealand Launch Up-to-$5.3B Obesity Collaboration
(1d)
Fungus-Based Nanoparticles Can Battle Infections and Cancer
(1d)
AI, IoT, and the Future of Biopharma Manufacturing
(1d)
Cure Today
Antihistamines Associated With Bladder Cancer Survival, Progression Improvements
(1h)
Dr. Kevin Kalinsky Covers Targeted Therapy in HER2– Breast Cancer
(3h)
Trusting My Stage 4 Breast Cancer Body
(5h)
ctDNA Testing May Offer Patients With RCC ‘Peace of Mind’
(6h)
First Patient Dosed With Recombinant Bacillus Calmette-Guérin in Bladder Cancer
(7h)
Xtandi and Talzenna Therapy Shows Responses in Advanced Prostate Cancer
(9h)
Tedopi Cancer Vaccine Meets Trial End Point For Pancreatic Cancer
(1d)
Bringing Together the CAR T-Cell Therapy Community
(1d)
Nutrition is Key Following a Cancer Diagnosis
(1d)
The Leukemia & Lymphoma Society is Helping Patients With Medial Debt
(1d)
Contract Pharma*
What’s New: Business Updates from Across the OSD Sector
(6h)
Batavia Biosciences Partners with VBC & MEVAC to Enhance Vaccine Manufacturing Capabilities in Egypt
(6h)
Mallinckrodt and Endo Agree to Combine
(7h)
Coronado Research Appoints Nick Littlebury as EVP of Regulatory Affairs
(7h)
Bristol Meyers Squibb to Acquire 2seventy bio
(7h)
MeiraGTx Enters a Strategic Collaboration with Hologen AI
(7h)
Grifols IVIG Shows Promise for Post-Polio Syndrome
(8h)
Dsm-Firmenich Launches Taste Solutions Portfolio for Pharmaceutical Applications
(8h)
Boehringer Ingelheim Taps Salipro Biotech to Accelerate Pipeline Programs
(8h)
PranaX Taps Philip Maderia as CEO
(9h)
The Pharma Letter*
Gene therapy for Parkinson’s at heart of new AI collab
(2h)
Troubled Mallinckrodt and Endo to merge
(5h)
Salipro Biotech inks deal with Boehringer
(5h)
Sareum sees future for cancer asset
(6h)
SOTIO takes up option on Synaffix ADCs
(6h)
Pharming reports revenue growth and strategic expansion in 2024
(7h)
Steqeyma, a biosimilar to Stelara, now available in the USA
(7h)
Results point to potential of Ashvattha’s migaldendranib
(9h)
Insilico takes in $110 million for AI-driven pipeline
(9h)
Heidelberg secures $20 million in amended royalty financing
(9h)
Targeted Oncology
Exploring Newer Treatment Options With Tagraxofusp in BPDCN
(1h)
Experts Discuss Tislelizumab’s FDA Approval in Esophageal Cancer
(3h)
Dr. Galsky’s Perspectives on the CheckMate 274 Data Results
(4h)
Clinical Perspectives for the Treatment of R/M NPC
(4h)
Phase 3 CheckMate 274 Study: Adjuvant Nivolumab for High-Risk MIUC—Updated Results
(4h)
Treatment Paradigms in R/M NPC: The Role of Systemic Immunotherapy
(4h)
Treatment Landscape of Recurrent NPC: Evaluating First-Line Toripalimab in the Recurrent Setting
(4h)
A 48-Year-Old Man With Recurrent NPC
(4h)
Phase 3 CheckMate 274 Study: Adjuvant Nivolumab for High-Risk MIUC—Aims and Design
(4h)
An Introduction to NPC
(4h)
MedWatch*
AJ Vaccines' bylaws block CEO's wish for women on the board
(7h)
Genmab re-elects board of directors at AGM
(8h)
Eli Lilly chief's salary surged to USD 29.2m in 2024
(8h)
US drug compounders challenge FDA decision to remove obesogens from shortage list
(8h)
Trade association for compounded drugs oppose FDA removal of obesogens from shortage list
(8h)
Trade association opposes FDA's decision to remove obesogens from shortage list
(8h)
Trade association opposes FDA decision to remove obesogens from shortage list
(8h)
Trade association opposes FDA decision to remove weight-loss drugs from shortage list
(8h)
Supplier for troubled Novo Nordisk building project dropped after critical media coverage
(10h)
Digital medtech company receives FDA clearance
(10h)
In The Pipeline
Crystallization Cages
(4h)
A Bifunctional Degrader Reads Out in Phase 3
(1d)
New Synthetic Antibiotics
(2d)
Single-Base Editing Seems to Work
(3d)
Bird is the (Geomagnetic) Word
(7d)
The Continuing Crisis, Part VII: An Overview
(1w)
The Continuing Crisis, Part VI: Rare Diseases at the FDA and More
(1w)
Progress on RNA-Based Cancer Vaccines
(1w)
The Thiazide Target, At Last
(2w)
Neurodegeneration Might Come Down to RNA
(2w)
Pharmaphorum
Trump pulls CDC head nomination as FDA, CDC picks advance
(7h)
Insilico raises $110m for AI-designed drug pipeline
(8h)
'Transformational' pill for endometriosis gets NHS nod
(8h)
UK PM Keir Starmer reveals plan to abolish NHS England
(10h)
Is Mallinckrodt about to merge with Endo?
(11h)
Rumour confirmed as Mallinckrodt merges with Endo
(11h)
Kelun-Biotech first to bag TROP2 approval in lung cancer
(12h)
Roche builds in obesity with $5.3bn Zealand licensing deal
(1d)
Gates-backed game aims to raise HPV awareness in Africa
(1d)
EU proposes legislation to bolster medicines supply chain
(1d)
Drug Discovery Weekly
First patient dosed in gene therapy study for Stargardt disease
(5h)
New podcast: The revolutionary impact of understanding genomics
(7h)
The revolutionary impact of understanding genomics
(7h)
BMS buys CAR-T company 2seventy bio
(9h)
First clinical genetic correction of a disease-causing mutation reported
(11h)
New generative AI tool halves research time, data suggests
(12h)
The automation revolution in drug discovery
(13h)
Webinar highlights innovation in therapeutic antibody discovery
(13h)
Pharma/biotech biparatopic antibody collaboration agreed
(1d)
A global overview of therapeutic antibody development
(1d)
Reddit Biotech
Which Job Do I Choose?
(1h)
Feeling Stuck After M.Sc. Biotech—Can’t Land a Job, Need Advice
(2h)
Applied to a job again months later after doing final interview
(2h)
Genentech community college internship 2025
(2h)
Noncompete?
(3h)
Canada: Job perspective for Masters in Life Science? Should I switch to nursing at this point?
(3h)
Not having a good time being a biotech contractor
(5h)
Cure for rabbies??
(6h)
Academia to industry for Systems Biology
(6h)
Contracting Question
(7h)
Google News Biotech
Evaxion Biotech A/S Files For Stock Shelf Of Up To $50 Million -March 13, 2025 at 05:32 pm EDT - Marketscreener.com
(29m)
Portage Biotech Inc. Announces New Director Compensation Plan and Stock Option Grants - TipRanks
(1h)
Bio-Tech Flavor Market Growth forecast 2034: valuation expected to reach $69.03 billion at a CAGR of 7.2% - Global Banking And Finance Review
(2h)
Kane Biotech To Begin Clinical Trial For DispersinB Acne Cleanser Following IRB Approval - Nasdaq
(2h)
George Church spinout GRObio explores strategic alternatives 6 months after Bayer-backed series B - Fierce Biotech
(4h)
Salipro Biotech inks deal with Boehringer
(5h)
Biotech Alert: Searches spiking for these stocks today - TipRanks
(5h)
VUB to strengthen Brussels' position in biotech sector - The Brussels Times
(5h)
Sotio takes up option on ADCs, Boehringer inks discovery pact - Fierce Biotech
(7h)
Biotech startup Insilico has increased its value to $1 billion in financing - AK&M News
(7h)
* May require subscription